Integer Holdings Corporation is a medical device contract development and manufacturing organization serving the Cardio and Vascular, Neuromodulation, and Cardiac Rhythm Management markets. The company designs, develops, and manufactures components, subassemblies, and finished devices, including coronary stents, balloon catheters, guidewires, introducer sheaths, pacemaker batteries, and neuromodulation systems. Integer operates through its Greatbatch Medical and Lake Region Medical brands, providing solutions for interventional cardiology, structural heart, electrophysiology, and vascular access procedures. Its customers include large multinational original equipment manufacturers and their subsidiaries. The company has expanded its capabilities through acquisitions of Biocoat, VSi Parylene, and Precision Coating, adding surface coating technologies such as hydrophilic, parylene, and fluoropolymer coatings. Integer serves global markets with a focus on advanced medical device outsourcing and rapid prototyping.

Summarised from the company's own disclosures, fiscal year ended Feb 2026

Industry Medical Devices Homepage integer.net
Sector Healthcare IR page investor.integer.net/overview/default.aspx
Tags
contract manufacturing, cardiovascular devices, neuromodulation, cardiac rhythm management, catheters, guidewires, stents, pacemaker batteries, surface coatings, medical device oem, Greatbatch Medical, Lake Region Medical, Biocoat, VSi Parylene, Precision Coating
Press page —

Metrics

Valuation  
Market cap $ 4.318B
Market cap (USD) $ 4.318B
P/E 42.33
PEG 2.60
P/BV 2.50
P/S 2.37
P/OCF 24.47
P/FCF 52.77
Dividend yield —
Turnover / mcap —
Returns  
ROE 6.1%
ROI 3.5%
ROIC 6.2%
Profit margin 5.5%
Growth  
Revenue growing Yes
Profits growing No
Revenue up 3y Yes
Revenue up 5y Yes
Earnings growth 3y (net profit CAGR) 16.3%
Quality  
Profitable Yes
Margin expanding No
Buying back stock No
Diluting (TTM) No
Debt/Equity 70.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 40
Quality score -5.9%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Revenue 1.854B 1.717B 1.597B 1.376B 1.221B 1.073B 1.258B 1.215B 1.462B 1.387B 800.414M 687.787M 663.945M 646.177M 568.822M 533.425M 521.821M 546.644M 318.746M 271.142M 241.097M 200.119M 216.365M 167.296M 135.575M 97.79M
Net profit 102.808M 119.896M 90.65M 66.377M 96.808M 77.258M 96.336M 167.964M 66.679M 5.961M -7.594M 55.458M 36.267M -4.799M 33.122M 33.138M -9.001M 18.559M 15.05M 16.126M 10.107M 14.218M 23.288M 14.361M 8.597M -548K
Free cash flow 105.116M 99.848M 60.275M 41.653M 103.203M 134.509M 117.16M 122.391M 102.056M 46.9M -32.137M 56.453M 38.197M 23.762M 67.432M 60.745M 52.092M 12.929M 22.972M 23.76M 15.152M 6.722M 42.876M 7.309M 11.74M 13.632M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018 FY 2017 FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 FY 2011 FY 2010 FY 2009 FY 2008 FY 2007 FY 2006 FY 2005 FY 2004 FY 2003 FY 2002 FY 2001 FY 2000
Share price 78.43 132.52 99.08 68.46 85.59 81.19 80.43 76.26 45.3 29.45 — — — — — — — — — — — — — — — —
Price performance 12m -0.41 0.34 0.45 -0.2 0.05 0.01 0.05 0.68 0.54 — — — — — — — — — — — — — — — — —

Filed figures

Figure Dec 2016 Dec 2017 Dec 2018 Dec 2019 Dec 2020 Dec 2021 Dec 2022 Dec 2023 Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) 205M 242M 186M 192M 156M 182M 224M 238M 245M 346M
↳ YoY growth -1.3% +18.5% -23.5% +3.5% -18.6% +16.7% +23.0% +6.2% +2.9% +41.1%
↳ 5y CAGR +15.0% +14.9% +10.3% +9.0% -5.5% -2.3% -1.5% +5.1% +5.0% +17.2%
Borrowings, current (USD) 31.3M 30.5M 37.5M 37.5M 37.5M 15.3M 18.2M 0.00 10M 0.00
Borrowings, non-current (USD) 1.7B 1.58B 888M 777M 694M 813M 907M 960M 980M 1.19B
Lease liabilities (USD) — — 0.00 44.6M 46.3M 77.7M 83.5M 93.3M 113M 127M
Cash and deposits (USD) 52.1M 44.1M 25.6M 13.5M 49.2M 17.9M 24.3M 23.7M 46.5M 17.2M
Intangible assets (USD) 850M 920M 812M 776M 757M 808M 820M 783M 778M 825M
Right-of-use assets (USD) — — — 42.4M 45.2M 70.1M 74.8M 81.6M 86.1M 98.4M
Net debt (borrowings + leases - cash) (USD) 1.68B 1.57B 900M 846M 728M 888M 984M 1.03B 1.06B 1.3B
Cash flow detail
Operating cash flow (USD) 106M 149M 167M 165M 181M 157M 116M 180M 205M 196M
Purchases of property, plant and equipment (USD) -58.6M -47.3M -44.9M -48.2M -46.8M -53.5M -74.7M -120M -105M -91M
Purchases of intangible assets (USD) — — 0.00 0.00 -4.61M 0.00 0.00 0.00 -250,000 —
Change in receivables (cash effect) (USD) -2.17M -34.6M 9.29M -6.98M 38.2M -17.5M -41.4M -7.44M -6.53M -82.4M
Change in inventories (cash effect) (USD) 22.2M -986,000 -16.1M 3.72M 18.4M 4.7M -56.7M -30.2M -18.1M -2.58M
Change in payables (cash effect) (USD) -1.13M 4.89M -94,000 1.89M -9.06M 19.5M 26M -520,000 -16.6M -566,000
Share buybacks (cash effect) (USD) — — — — — — — 0.00 0.00 -50M
Interest paid (cash effect) (USD) -106M -93.8M -79.7M -44.8M -33.9M -24.7M -35.8M -37.7M -54.2M -32.4M
Income taxes paid (cash effect) (USD) -7.26M 8.19M -23.2M -30M -18.5M -19.6M -11.2M -30.4M -36.5M -28.2M
Share-based compensation (USD) 8.41M 14.7M 10.5M 9.29M 9.16M 16.2M 21M 23.3M 24.8M 23.2M
Operating cash flow before change in receivables (USD) 108M 184M 158M 172M 143M 174M 158M 188M 212M 279M
Free cash flow (OCF - PPE - intangibles) (USD) 46.9M 102M 122M 117M 130M 103M 41.7M 60.3M 99.6M 105M
Income detail
Research and development expense (USD) 55M 55.2M 48.6M 46.5M 48.5M 52M 60.9M 63.8M 53.4M 49.5M
↳ 5y CAGR +3.9% +1.0% -2.1% -1.4% -1.8% -1.1% +2.0% +5.6% +2.8% +0.4%
Total comprehensive income (USD) -11.4M 135M 148M 83.3M 110M 71.3M 44.5M 106M 85.6M 175M
Comprehensive income to owners (USD) -11.4M 135M 148M 83.3M 110M 71.3M 44.5M 106M 85.6M 175M
Reported Feb 28, 2017 Feb 22, 2018 Feb 18, 2021 Feb 18, 2021 Feb 18, 2021 Feb 22, 2022 Feb 21, 2023 Feb 23, 2026 Feb 23, 2026 Feb 23, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

1.875% Convertible Senior Notes due 2030 in Connection with Completed Merger

PLANO, Texas, Nov. 17, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (“Integer” or the “Company”), a leading medical device contract development and manufacturing organization, today delivered notices (each, a “Notice” and together, the “Notices”) to holders of its 2.125% Convertible Senior Notes due 2028 (the “2028 Notes”) and its 1.875% Convertible Senior Notes due 2030 (the “2030 Notes” and, together with the 2028 Notes, the “Notes”), pursuant to the Indenture, dated as of February 3, 2023, governing the 2028 Notes, and the Indenture, dated as of March 18, 2025, governing the 2030 Notes (each, an “Indenture”), in each case between the Company and Wilmington Trust, National Association, as trustee (the “Trustee”), that a Make-Whole Fundamental Change and a Fundamental Change (each as defined in the applicable Indenture) occurred under each Indenture on November 17, 2026 (the “Effective Date”).

On the Effective Date, the Company completed its previously announced merger (the “Merger”) with Armstrong Bidco, Inc., a wholly owned subsidiary of Armstrong Parent, Inc.

October 29, 2026

PLANO, Texas, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE:ITGR) today announced results for the three months ended October 2, 2026.

Third Quarter 2026 Highlights (compared to Third Quarter 2025, except as noted)

  • Sales decreased 3.9% to $450 million. Organic sales decreased 2.2%.
  • GAAP operating income from continuing operations totaled $28 million, a decrease of $28 million or 50%. Non-GAAP adjusted operating income totaled $66 million, a decrease of $20 million or 23%.
  • GAAP income from continuing operations totaled $15 million, a decrease of $25 million or 62%. Non-GAAP adjusted net income totaled $46 million, a decrease of $17 million or 27%.
  • GAAP diluted EPS from continuing operations totaled $0.43, a decrease of $0.68 or 61%. Non-GAAP adjusted EPS totaled $1.34, a decrease of $0.45 or 25%.
  • Adjusted EBITDA  totaled $88 million, a decrease of $18 million or 17%.
  • From the end of 2025, total debt increased $34 million to $1.219 billion and Non-GAAP net total debt increased $33 million to $1.223 billion, resulting in a leverage ratio of 3.3 times adjusted EBITDA as of October 2, 2026.

As previously announced, given Integer’s pending acquisition by an affiliate of investment funds managed by KKR (the “Transaction”) pursuant to the Agreement and Plan of Merger, dated as of August 2, 2026, by and among Integer, Armstrong Parent, Inc. (“Parent”), and Armstrong Bidco, Inc. (the “Merger Agreement”), the Company is not providing a financial outlook and will not host a conference call to discuss its third quarter 2026 financial results. On September 29, 2026, the Company received early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and on October 21, 2026, Integer's stockholders approved the adoption of the Merger Agreement. The Transaction is anticipated to close by the end of 2026, subject to the satisfaction or waiver of the remaining customary closing conditions specified in the Merger Agreement, including receipt of required regulatory approvals.

Discussion of Product Line Third Quarter 2026 Sales

  • Cardio & Vascular sales decreased 5% to $263 million in the third quarter 2026 compared to the third quarter 2025, reflecting the previously communicated impact from the two new Electrophysiology products.
  • Cardiac Rhythm Management & Neuromodulation sales increased 4% to $176 million in the third quarter 2026 compared to the third quarter 2025. Growth was partially offset by the previously communicated impact from the one new Neuromodulation product.
  • Other Markets sales totaled $11 million in the third quarter 2026, compared to $21 million in the third quarter 2025, primarily due to the Portable Medical exit.  
Summary Financial Results (dollars in thousands, except per share data)
Three Months Ended Nine Months Ended
October 2, 2026 September 26, 2025 QTD Change October 2, 2026 September 26, 2025 YTD Change
Operating income $ 28,209 $ 56,439 (50.0) % $ 94,606 $ 165,329 (42.8)%
Income from continuing operations $ 14,978 $ 39,678 (62.3) % $ 55,089 $ 54,222 1.6%
Diluted EPS from continuing operations $ 0.43 $ 1.11 (61.3) % $ 1.60 $ 1.52 5.3%
EBITDA**(a)** $ 61,563 $ 88,399 (30.4) % $ 194,623 $ 207,673 (6.3)%
Adjusted EBITDA**(a)** $ 87,916 $ 105,898 (17.0) % $ 267,916 $ 296,358 (9.6)%
Adjusted operating income**(a)** $ 66,290 $ 85,896 (22.8) % $ 200,334 $ 238,085 (15.9)%
Adjusted net income**(a)** $ 46,140 $ 63,126 (26.9) % $ 142,142 $ 163,882 (13.3)%
Adjusted EPS**(a)** $ 1.34 $ 1.79 (25.1) % $ 4.14 $ 4.64 (10.8)%
(a) EBITDA, adjusted EBITDA, Adjusted operating income, Adjusted net income, and Adjusted EPS are non-GAAP financial measures. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures. Refer to Tables A, B and C at the end of this release for reconciliations of adjusted amounts to the closest corresponding GAAP financial measures.
Summary Product Line Results (dollars in thousands)
Three Months Ended
October 2, 2026 September 26, 2025 QTD Change
Product Line Sales
Cardio & Vascular $ 263,076 $ 277,149 (5.1)%
Cardiac Rhythm Management & Neuromodulation 175,835 169,156 3.9%
Other Markets 10,750 21,386 (49.7)%
Total Sales $ 449,661 $ 467,691 (3.9)%
Nine Months Ended
October 2, 2026 September 26, 2025 YTD Change
Product Line Sales
Cardio & Vascular $ 805,117 $ 822,875 (2.2) %
Cardiac Rhythm Management & Neuromodulation 517,811 501,499 3.3%
Other Markets 30,423 57,203 (46.8) %
Total Sales $ 1,353,351 $ 1,381,577 (2.0) %
(a) Organic sales change is a non-GAAP financial measure. Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures and refer to Table D at the end of this release for a reconciliation of these amounts to the closest corresponding GAAP financial measures.

**
About Integer®**

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The company's brands include Greatbatch Medical**®** and Lake Region Medical**®**. Additional information is available at www.integer.net .

Investor Relations:

Kristen Stewart
551-337-3973
[email protected]

Notes Regarding Non-GAAP Financial Information

In addition to our results reported in accordance with generally accepted accounting principles in the United States of America (“GAAP”), we provide adjusted net income, adjusted EPS, earnings before interest, taxes, depreciation and amortization (“EBITDA”), adjusted EBITDA, adjusted operating income, and organic sales change. Unless otherwise indicated, all financial metrics presented reflect continuing operations only.

Adjusted net income and adjusted EPS consist of GAAP income (loss) from continuing operations and diluted EPS from continuing operations, respectively, adjusted for the following to the extent occurring during the period: (i) amortization of intangible assets, (ii) certain legal expenses; (iii) restructuring and restructuring-related charges; (iv) acquisition and integration costs; (v) other general expenses; (vi) ERP implementation, (vii) (gain) loss on equity investments; (viii) extinguishment of debt charges, (ix) debt conversion inducement expense; (x) European Union medical device regulation incremental charges; (xi) inventory step-up amortization; (xii) unusual, or infrequently occurring items; (xiii) the income tax provision (benefit) related to these adjustments and (xiv) certain tax items that are outside the normal tax provision for the period. Adjusted EPS is calculated by dividing adjusted net income by adjusted weighted average shares.

The weighted average shares used to calculate diluted EPS in accordance with GAAP includes dilution, when applicable, resulting from the potential conversion of our 2028 Convertible Notes and 2030 Convertible Notes (collectively, the “Convertible Notes”).  In connection with the issuance of the Convertible Notes, we entered into capped call contracts which are expected to reduce the potential dilution on our common stock in connection with any conversion of the Convertible Notes, subject to a cap.  Adjusted weighted average shares consists of GAAP weighted average shares used to calculate diluted EPS, including, when applicable, dilutive common stock equivalents that were excluded from weighted average shares used to calculate diluted EPS as their inclusion would be anti-dilutive and excluding, when applicable, dilution resulting from the potential conversion of our Convertible Notes expected to be offset by the capped call contracts.

EBITDA is calculated by adding back interest expense, provision for income taxes, depreciation expense, and amortization expense from intangible assets and financing leases, to income (loss) from continuing operations, which is the most directly comparable GAAP financial measure. Adjusted EBITDA consists of EBITDA plus adding back stock-based compensation and the same adjustments as listed above except for items (i), (viii), (xiii) and (xiv). Adjusted operating income consists of operating income adjusted for the same items listed above except for items (vii), (viii), (ix), (xiii) and (xiv).

Organic sales change is reported sales growth adjusted to remove the impact of foreign currency, the contribution of acquisitions and the strategic exit of the Portable Medical market. To calculate the impact of foreign currency on sales growth rates, we convert any sale made in a foreign currency by converting current period sales into prior period sales using the exchange rate in effect at that time and then compare the two, negating any effect foreign currency had on our transactional revenue. For contribution of acquisitions, we exclude the impact on the growth rate attributable to the contribution of acquisitions in all periods where there were no comparable sales. For the strategic exit of the Portable Medical market, we exclude the impact on the growth rate attributable to Portable Medical sales for all periods presented.

We believe that the presentation of adjusted net income, adjusted EPS, EBITDA, adjusted EBITDA, adjusted operating income, and organic sales change, provides important supplemental information to management and investors seeking to understand the financial and business trends relating to our financial condition and results of operations. In addition to the performance measures identified above, we believe that net total debt and leverage ratio provide meaningful measures of liquidity and a useful basis for assessing our ability to fund our activities, including the financing of acquisitions and debt repayments. Net total debt is calculated as total principal amount of debt outstanding less cash and cash equivalents. We calculate leverage ratio as net total debt divided by adjusted EBITDA for the trailing 4 quarters.

Cautionary Statement Regarding Forward-Looking Statements

Some of the statements contained in this communication and other written and oral statements made from time to time by us and our representatives are not statements of historical or current fact. As such, they are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended and are subject to the safe harbor created thereby under the Private Securities Litigation Reform Act of 1995. We have based these forward-looking statements on our current expectations, and these statements are subject to known and unknown risks, uncertainties and assumptions. Forward-looking statements include, but are not limited to, statements relating to: the completion of the Transaction on anticipated terms and timing, or at all, including obtaining regulatory approvals and satisfying other conditions to the completion of the Transaction; potential litigation relating to the Transaction that has been or could be instituted against the parties to the Merger Agreement, or their respective directors, managers, or officers, including the effects of any outcomes related thereto; our goals, plans, and strategic initiatives; long-term growth prospects; maximizing value for our stockholders; other events, conditions or developments that will or may occur in the future; and the timing of any of the foregoing. You can identify forward-looking statements by terminology such as “may,” “will,” “should,” “could,” “expects,” “intends,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “forecast,” “outlook,” “assume,” “potential” or “continue” or variations or the negative counterparts of these terms or other comparable terminology. These statements are only predictions and are not guarantees of future performance, and investors should not place undue reliance on forward-looking statements as predictive of future results. Actual events or results may differ materially from those stated or implied by these forward-looking statements. In evaluating these statements and our prospects, you should carefully consider the factors set forth below. All forward-looking statements attributable to us or persons acting on our behalf are expressly qualified in their entirety by these cautionary factors and by others contained throughout this communication.

Forward-looking statements by their nature address matters that are, to different degrees, uncertain, such as statements regarding the Transaction. All such forward-looking statements are based upon current plans, estimates, expectations, opportunities and ambitions that are subject to risks, uncertainties, assumptions, and other important factors, many of which are beyond the control of the Company, that could cause actual results to differ materially from those expressed in such forward-looking statements. Key factors that could cause actual results to differ materially include, but are not limited to, the expected timing and likelihood of completion of the Transaction, including the timing, receipt and terms and conditions of any required governmental and regulatory approvals; the occurrence of any event, change or other circumstances that could give rise to the termination of the Transaction; the risk that the parties may not be able to satisfy the conditions to the Transaction in a timely manner or at all; risks related to disruption of management time from ongoing business operations due to the Transaction; the risk that any announcements relating to the Transaction could have adverse effects on the market price of the Company’s common stock; the risk that the Transaction and its announcement could have an adverse effect on the parties’ business relationships and business generally, including the ability of the Company to retain customers and retain and hire key personnel and maintain relationships with their suppliers and customers, and on their operating results and businesses generally; the risk of unforeseen or unknown liabilities; customer, regulatory and other stakeholder approvals and support; the risk of unexpected future capital expenditures; the risk of potential litigation relating to the Transaction that has been or could be instituted against the Company or its directors and/or officers; the risk associated with third-party contracts containing material consent, anti-assignment, transfer or other provisions that may be related to the Transaction which are not waived or otherwise satisfactorily resolved; significant costs, or expenses incurred in connection with the Transaction; Parent’s ability to obtain the necessary financing arrangements set forth in the commitment letters received in connection with the Transaction; certain restrictions contained in the Merger Agreement that may impact the Company’s ability to pursue certain business opportunities or strategic transactions; the risk of various events that could disrupt operations, including pandemics, epidemics or other public health crises or severe weather (such as droughts, floods, avalanches and earthquakes), cybersecurity attacks, security threats and governmental response to them, and technological changes; the risks of labor disputes, changes in labor costs and labor difficulties; and the risks resulting from other effects of industry, market, economic, legal or legislative, political or regulatory conditions outside of the Company’s control. All such factors are difficult to predict and are beyond our control, including those detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, which was filed with the Securities and Exchange Commission (the “SEC”) on February 23, 2026, the Company’s Quarterly Report on Form 10-Q for the fiscal quarter ended July 3, 2026, which was filed with the SEC on August 4, 2026, the Company’s definitive proxy statement filed with the SEC on September 14, 2026, as supplemented, and other documents subsequently filed by the Company with the SEC. The Company’s forward-looking statements are based on assumptions that the Company believes to be reasonable but that may not prove to be accurate. Other unpredictable factors not discussed in this communication could also have material adverse effects on forward-looking statements. The Company does not assume an obligation to update any forward-looking statements, except as required by applicable law. These forward-looking statements speak only as of the date hereof.

Condensed Consolidated Balance Sheets - Unaudited
(in thousands)
October 2, 2026 December 31, 2025
ASSETS
Current assets:
Cash and cash equivalents $ 14,135 $ 17,161
Accounts receivable, net 345,072 346,079
Inventories 278,591 253,739
Contract assets 119,297 112,546
Prepaid expenses and other current assets 44,297 40,572
Total current assets 801,392 770,097
Property, plant and equipment, net 535,133 536,427
Goodwill 1,100,799 1,110,908
Other intangible assets, net 770,089 825,435
Deferred income taxes 8,938 8,994
Operating lease assets 82,586 98,437
Financing lease assets 55,491 37,109
Other long-term assets 39,509 23,170
Total assets $ 3,393,937 $ 3,410,577
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable $ 111,003 $ 113,130
Operating lease liabilities 8,359 9,099
Accrued expenses and other current liabilities 81,763 109,812
Total current liabilities 201,125 232,041
Long-term debt 1,219,247 1,185,179
Deferred income taxes 113,596 116,327
Operating lease liabilities 67,371 81,899
Financing lease liabilities 49,577 28,578
Other long-term liabilities 16,622 19,910
Total liabilities 1,667,538 1,663,934
Stockholders’ equity:
Common stock 35 35
Additional paid-in capital 761,271 771,223
Treasury stock (110,334 ) (76,872 )
Retained earnings 1,049,144 994,055
Accumulated other comprehensive income 26,283 58,202
Total stockholders’ equity 1,726,399 1,746,643
Total liabilities and stockholders’ equity $ 3,393,937 $ 3,410,577
Condensed Consolidated Statements of Operations - Unaudited
(in thousands, except per share data)
Three Months Ended Nine Months Ended
October 2, 2026 September 26, 2025 October 2, 2026 September 26, 2025
Sales $ 449,661 $ 467,691 $ 1,353,351 $ 1,381,577
Cost of sales 348,100 341,531 1,029,253 1,005,947
Gross profit 101,561 126,160 324,098 375,630
Operating expenses:
Selling, general and administrative 54,147 50,451 170,557 154,534
Research, development and engineering 13,528 10,949 41,049 39,390
Restructuring and other charges 5,677 8,321 17,886 16,377
Total operating expenses 73,352 69,721 229,492 210,301
Operating income 28,209 56,439 94,606 165,329
Interest expense 9,701 9,367 29,570 33,926
(Gain) loss on equity investments (31 ) (50 ) 1,395 (223 )
Other loss, net 1,027 1,130 2,487 53,037
Income from continuing operations before taxes 17,512 45,992 61,154 78,589
Provision (benefit) for income taxes 2,534 6,314 6,065 24,367
Income from continuing operations 14,978 39,678 55,089 54,222
Loss from discontinued operations, net of tax — — — (22 )
Net income $ 14,978 $ 39,678 $ 55,089 $ 54,200
Basic earnings per share:
Income from continuing operations $ 0.44 $ 1.13 $ 1.62 $ 1.56
Loss from discontinued operations $ — $ — $ — $ —
Basic earnings per share $ 0.44 $ 1.13 $ 1.62 $ 1.56
Diluted earnings per share:
Income from continuing operations $ 0.43 $ 1.11 $ 1.60 $ 1.52
Loss from discontinued operations $ — $ — $ — $ —
Diluted earnings per share $ 0.43 $ 1.11 $ 1.60 $ 1.52
Weighted average shares outstanding:
Basic 34,027 35,081 34,106 34,689
Diluted 34,604 35,608 34,394 35,755
Condensed Consolidated Statements of Cash Flows - Unaudited
(in thousands)
Nine Months Ended
October 2, 2026 September 26, 2025
Cash flows from operating activities:
Net income $ 55,089 $ 54,200
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization 103,899 95,158
Debt related charges included in interest expense 4,910 5,239
Debt conversion inducement expense — 46,681
Stock-based compensation 17,273 17,467
Non-cash fixed asset impairment 7,141 —
Non-cash lease expense 7,283 7,583
Non-cash (gains) losses on equity investments 1,395 (223 )
Contingent consideration fair value adjustment (1,179 ) (660 )
Other non-cash losses 4,043 804
Deferred income taxes 17 4,082
Gain on sale of discontinued operations — (46 )
Changes in operating assets and liabilities, net of acquisitions:
Accounts receivable (98 ) (46,793 )
Inventories (28,474 ) (12,241 )
Prepaid expenses and other assets (4,110 ) 117
Contract assets (7,255 ) (2,106 )
Accounts payable 2,137 3,187
Accrued expenses and other liabilities (29,421 ) (22,359 )
Income taxes payable (11,589 ) (9,357 )
Net cash provided by operating activities 121,061 140,733
Cash flows from investing activities:
Acquisition of property, plant and equipment (67,181 ) (63,555 )
Purchase of equity and other investments (14,043 ) —
Acquisitions, net — (170,872 )
Other investing activities 126 (835 )
Net cash used in investing activities (81,098 ) (235,262 )
Cash flows from financing activities:
Principal payments of long-term debt — (657,697 )
Proceeds from issuance of convertible notes, net of discount — 977,500
Proceeds from revolving credit facility 221,000 301,000
Payments of revolving credit facility (191,000 ) (427,000 )
Purchase of capped calls — (71,000 )
Payment of debt issuance costs (38 ) (1,386 )
Proceeds from the exercise of stock options — 3,644
Tax withholdings related to net share settlements of restricted stock unit awards (10,419 ) (16,812 )
Repurchases of common stock (50,000 ) —
Principal payments on finance leases (6,558 ) (4,165 )
Other financing activities (5,163 ) 1,194
Net cash provided by (used in) financing activities (42,178 ) 105,278
Effect of foreign currency exchange rates on cash and cash equivalents (811 ) 1,652
Net increase (decrease) in cash and cash equivalents (3,026 ) 12,401
Cash and cash equivalents, beginning of period 17,161 46,543
Cash and cash equivalents, end of period $ 14,135 $ 58,944
Table A: Adjusted Net Income and Diluted EPS from Continuing Operations Reconciliations (in thousands, except per share amounts)
Three Months Ended
October 2, 2026 September 26, 2025
Pre-Tax Net of Tax Per Diluted Share(a) Pre-Tax Net of Tax Per Diluted Share(a)
Income from continuing operations (GAAP) $ 17,512 $ 14,978 $ 0.43 $ 45,992 $ 39,678 $ 1.11
Adjustments(b):
Amortization of intangible assets 15,749 12,718 0.37 16,249 13,088 0.37
Certain legal expenses (SG&A)(c) 828 655 0.02 181 144 —
Restructuring and restructuring-related charges(d) 4,666 3,720 0.11 2,749 2,196 0.06
Acquisition and integration costs(e) 102 82 — 1,372 1,087 0.03
Other general expenses(f) 4,176 3,310 0.10 6,247 4,764 0.13
ERP implementation(g) 3,947 3,119 0.09 — — —
(Gain) loss on equity investments(h) (31 ) (24 ) — (50 ) (39 ) —
Medical device regulations(i) 45 35 — 183 145 —
Other adjustments(j) 8,568 6,768 0.20 2,476 1,956 0.06
Tax adjustments(k) — 779 0.02 — 107 —
Adjusted net income (non-GAAP) $ 55,562 $ 46,140 $ 1.34 $ 75,399 $ 63,126 $ 1.79
Nine Months Ended
October 2, 2026 September 26, 2025
Pre-Tax Net of Tax Per Diluted Share(a) Pre-Tax Net of Tax Per Diluted Share(a)
Income from continuing operations (GAAP) $ 61,154 $ 55,089 $ 1.60 $ 78,589 $ 54,222 $ 1.52
Adjustments(b):
Amortization of intangible assets 47,716 38,538 1.12 47,220 38,015 1.08
Certain legal expenses (SG&A)(c) 2,967 2,344 0.07 292 231 0.01
Restructuring and restructuring-related charges(d) 10,911 8,392 0.24 6,426 5,134 0.15
Acquisition and integration costs(e) 1,717 1,366 0.04 8,121 6,434 0.18
Other general expenses(f) 12,322 10,178 0.30 6,253 4,770 0.14
ERP implementation(g) 12,221 9,655 0.28 — — —
(Gain) loss on equity investments(h) 1,395 1,102 0.03 (223 ) (176 ) —
Loss on extinguishment of debt(l) — — — 867 685 0.02
Debt conversion inducement expense(m) — — — 46,681 46,681 1.32
Medical device regulations(i) 389 307 0.01 695 549 0.02
Other adjustments(j) 17,485 13,813 0.40 3,749 2,962 0.08
Tax adjustments(k) — 1,358 0.04 — 4,375 0.12
Adjusted net income (Non-GAAP) $ 168,277 $ 142,142 $ 4.14 $ 198,670 $ 163,882 $ 4.64
(a) Income from continuing operations (GAAP) per diluted share amounts are calculated in accordance with GAAP using weighted average shares for diluted EPS.  The per share amounts for the adjustments in the table above and adjusted net income are calculated using adjusted weighted average shares. The following table provides a reconciliation from GAAP weighted average shares for diluted EPS to non-GAAP adjusted weighted average shares.
Three Months Ended Nine Months Ended
October 2, 2026 September 26, 2025 October 2, 2026 September 26, 2025
Weighted average shares for diluted EPS (GAAP) 34,604 35,608 34,394 35,755
Less: 2028 Convertible Notes capped call options impact (244 ) (261 ) (90 ) (430 )
Adjusted weighted average shares (non-GAAP) 34,360 35,347 34,304 35,325
(b) The difference between pre-tax and net of tax amounts is the estimated tax impact related to the respective adjustment. Net of tax amounts are computed using a 21% U.S. tax rate, and the statutory tax rates applicable in foreign tax jurisdictions, as adjusted for the existence of net operating losses (“NOLs”). Expenses that are not deductible for tax purposes (i.e. permanent tax differences) are added back at 100%.
(c) Certain legal expenses associated with non-ordinary course legal matters. Amounts for the third quarter and first nine months of 2026 include $0.7 million and $2.5 million, respectively, of expense incurred in connection with the Company’s defense of a securities class action lawsuit.
(d) We initiate discrete restructuring programs primarily to realign resources to better serve our customers and markets, improve operational efficiency and capabilities, and lower operating costs or improve profitability. Depending on the program, restructuring charges may include termination benefits, contract termination, facility closure and other exit and disposal costs. Restructuring-related expenses are directly related to the program and may include retention bonuses, accelerated depreciation, consulting expense and costs to transfer manufacturing operations among our facilities. Amounts for the third quarter and first nine months of 2026 include $2.2 million and $5.0 million, respectively, relating to our global manufacturing alignment restructuring initiative. In addition, the third quarter and first nine months of 2026 includes $0.6 million and $3.0 million, respectively, related to an organizational realignment to enhance execution of our strategy through dedicated focus on growth and operational excellence.
(e) Acquisition and integration costs are incremental costs that are directly related to a business or asset acquisition. These costs may include, among other things, professional, consulting and other fees, system integration costs, and fair value adjustments relating to contingent consideration.
(f) Other general expenses are discrete transactions occurring sporadically and affect period-over-period comparisons. The Company recorded fixed asset impairment charges during the third quarter and first nine months of 2026 of $1.2 million and $7.1 million, respectively, which were primarily due to revised expectations regarding the future use of certain fixed assets, and expense of $2.9 million and $4.4 million, respectively, related to termination benefits from actions to align labor with manufacturing volumes. The third quarter and first nine months of 2025 include $6.2 million related to termination benefits from actions to align labor with manufacturing volumes.
(g) These adjustments represent direct and incremental costs incurred in connection with our implementation of a new global enterprise resource planning ("ERP") solution and related IT transition costs. An implementation of this scale is a significant undertaking and will require substantial time and attention of management and key employees. The associated costs do not represent normal and recurring operating expenses and will be inconsistent in amounts and frequency making it difficult to contribute to a meaningful evaluation of our operating performance. Expenses for 2026 were primarily included in SG&A.
(h) Amounts reflect our share of equity method investee (gains) losses including unrealized appreciation/depreciation of the underlying interests of the investee.
(i) The charges represent incremental costs of complying with European Union medical device regulations for previously registered products and primarily include charges for contractors supporting the project and other direct third-party expenses.
(j) Other adjustments include costs which impact period-to-period comparability and do not represent the underlying ongoing results of our business. For 2025 and 2026, amounts include costs associated with leadership transitions, strategic projects, a stockholder activist matter, the Company’s strategic review and the Transaction, and a cyber incident. Other adjustments includes the following expenses (in millions):
Three Months Ended Nine Months Ended
October 2, 2026 September 26, 2025 October 2, 2026 September 26, 2025
Leadership transition costs $ — $ 1.0 $ 1.5 $ 1.7
Strategic projects 1.8 0.7 2.6 2.1
Stockholder activist matter 0.1 — 3.9 —
Strategic review and Transaction 6.9 — 8.2 —
Cyber incident costs 0.5 — 1.2 —
(k) Tax adjustments include changes to uncertain tax benefits and associated interest for all periods presented, and for 2026 also reflect nondeductible transaction costs. In addition, included in the amount for the first nine months of 2025 is the write off of a deferred tax asset for $4.1 million related to a portion of the unamortized original issue discount due to the partial exchange of the 2028 Convertible Notes.
(l) Loss on extinguishment of debt consists of accelerated write-offs of unamortized deferred debt issuance costs and discounts, which are included in interest expense.
(m) Debt conversion inducement expense relates to the partial exchange of the 2028 Convertible Notes and is recorded within Other loss, net in the Condensed Consolidated Statements of Operations.

Please see “Notes Regarding Non-GAAP Financial Information” for additional information regarding our use of non-GAAP financial measures.

Table B: Adjusted Operating Income Reconciliations (in thousands)
Three Months Ended Nine Months Ended
October 2, 2026 September 26, 2025 October 2, 2026 September 26, 2025
Operating income (GAAP) $ 28,209 $ 56,439 $ 94,606 $ 165,329
Adjustments:
Amortization of intangible assets 15,749 16,249 47,716 47,220
Certain legal expenses 828 181 2,967 292
Restructuring and restructuring-related charges 4,666 2,749 10,911 6,426
Acquisition and integration costs 102 1,372 1,717 8,121
Other general expenses 4,176 6,247 12,322 6,253
ERP implementation 3,947 — 12,221 —
Medical device regulations 45 183 389 695
Other adjustments 8,568 2,476 17,485 3,749
Adjusted operating income (non-GAAP) $ 66,290 $ 85,896 $ 200,334 $ 238,085
Table C: EBITDA and Adjusted EBITDA Reconciliations (in thousands)
Three Months Ended Nine Months Ended
October 2, 2026 September 26, 2025 October 2, 2026 September 26, 2025
Income from continuing operations (GAAP) $ 14,978 $ 39,678 $ 55,089 $ 54,222
Interest expense 9,701 9,367 29,570 33,926
Provision (benefit) for income taxes 2,534 6,314 6,065 24,367
Depreciation(a) 16,697 15,562 50,783 44,588
Amortization of intangible assets and financing leases 17,653 17,478 53,116 50,570
EBITDA (non-GAAP) 61,563 88,399 194,623 207,673
Stock-based compensation(b) 4,052 4,341 13,886 16,691
Certain legal expenses 828 181 2,967 292
Restructuring and restructuring-related charges 4,666 2,749 10,911 6,426
Acquisition and integration costs 102 1,372 1,717 8,121
Other general expenses 4,176 6,247 12,322 6,253
ERP implementation 3,947 — 12,221 —
(Gain) loss on equity investments (31 ) (50 ) 1,395 (223 )
Debt conversion inducement expense — — — 46,681
Medical device regulations 45 183 389 695
Other adjustments 8,568 2,476 17,485 3,749
Adjusted EBITDA (non-GAAP) $ 87,916 $ 105,898 $ 267,916 $ 296,358
(a) Excludes amounts included in Restructuring and restructuring-related charges.
(b) Total stock-based compensation expense less amounts included in Restructuring and restructuring-related charges, ERP implementation, and Other adjustments.
Table D: Organic Sales Change Reconciliation (% Change)
GAAP Reported Growth Impact of Foreign Currency(a) Impact of Strategic Exits and Acquisitions(a) Non-GAAP Organic Change
QTD Change (3Q 2026 vs. 3Q 2025)
Product Line
Cardio & Vascular (5.1)% (0.1)% 0.1% (5.1)%
Cardiac Rhythm Management & Neuromodulation 3.9% —% —% 3.9%
Other Markets (49.7)% —% (28.3)% (21.4)%
Total Sales (3.9)% —% (1.7)% (2.2)%
YTD Change (9M 2026 vs. 9M 2025)
Product Line
Cardio & Vascular (2.2)% 0.2% 0.3% (2.7)%
Cardiac Rhythm Management & Neuromodulation 3.3% —% —% 3.3%
Other Markets (46.8)% —% (30.9)% (15.9)%
Total Sales (2.0)% 0.1% (1.3)% (0.8)%
(a) Sales growth has been adjusted to exclude the impact of foreign currency exchange rate fluctuations, when applicable, and strategic exits and acquisitions.
Table E: Net Total Debt Reconciliation (in thousands)
October 2, 2026 December 31, 2025
Total debt $ 1,219,247 $ 1,185,179
Add: Debt discounts and deferred issuance costs included in Total debt 18,037 22,105
Total principal amount of debt outstanding 1,237,284 1,207,284
Less: Cash and cash equivalents 14,135 17,161
Net Total Debt (Non-GAAP) $ 1,223,149 $ 1,190,123

Primary Logo

Source: Integer Holdings Corporation

View All News

October 21, 2026

PLANO, Texas, Oct. 21, 2026 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR) (“Integer” or the “Company”) and Armstrong Parent, Inc. (“Parent”) today announced that, in connection with Parent’s proposed acquisition of the Company (the “Transaction”) contemplated by their Agreement and Plan of Merger, dated as of August 2, 2026 (the “Merger Agreement”), the stockholders of the Company have voted in favor of (1) the proposal to adopt the Merger Agreement and the Merger (the “First Proposal”) and (2) the proposal to approve, on an advisory (non-binding) basis, the compensation that will or may be paid or become payable to Integer’s named executive officers that is based on or otherwise related to the Transaction as contemplated in the Merger Agreement (the “Second Proposal”) at a special meeting of stockholders held on October 21, 2026 (the “Special Meeting”).

At the Special Meeting, (1) approximately 99.95% of the shares voted on the First Proposal were cast in favor of the First Proposal, representing approximately 76.66% of the total outstanding shares of Integer common stock as of the record date, September 8, 2026 (the “Record Date”), and (2) the Second Proposal was approved by a majority of the votes cast at the Special Meeting. The Company will provide a full report of the voting results from the Special Meeting in a Current Report on Form 8-K filed with the U.S. Securities and Exchange Commission (the “SEC”).

The Transaction is anticipated to close by the end of 2026, subject to the satisfaction or waiver of customary closing conditions specified in the Merger Agreement, including the receipt of required regulatory approvals.

About Integer**®**

Integer Holdings Corporation (NYSE: ITGR) is one of the largest medical device contract development and manufacturing organizations (CDMOs) in the world, serving the cardio and vascular, neuromodulation, and cardiac rhythm management markets. As a strategic partner of choice, we advance the goals of our medical device customers through industry-leading engineering and manufacturing, with a relentless commitment to quality, service, and innovation. The Company’s brands include Greatbatch Medical® and Lake Region Medical®. Additional information is available at www.integer.net .

Prompts

Integer Holdings Corporation (ticker ITGR), listed in United States.

Company History

Date Change Detail
Jul 1, 2016 Renamed GREATBATCH, INC. → INTEGER HOLDINGS CORP
May 7, 2007 Acquired Acquired Enpath Medical, Inc. (CIK 833140). Its filings from before the deal are on its own company page, not shown here.
Jun 3, 2005 Renamed WILSON GREATBATCH TECHNOLOGIES INC → GREATBATCH, INC.

ETFs Holding Integer Holdings Corporation

ETF Weight in ETF Shares Market value As of
EVNT 2.01% 2,103 $ 263.401K Aug 31, 2026
SQLV 0.35% 1,067 $ 99.711K Jun 30, 2026
PSC 0.22% 55,495 $ 5.186M Jun 30, 2026
RUSC 0.17% 1,474 $ 137.745K Jun 30, 2026
RESM 0.15% 57 $ 5,326.65 Jun 30, 2026
DXUV 0.03% 13,140 $ 1.661M Nov 12, 2026
MSSM 0.02% 1,277 $ 159.944K Aug 31, 2026
DFSU 0.01% 2,002 $ 253.093K Nov 12, 2026
DFAC 0.00% 31,346 $ 3.963M Nov 12, 2026
DCOR 0.00% 72 $ 9,102.24 Nov 12, 2026